Legal Representation
Attorney
Jenevieve Maerker, Esq.
USPTO Deadlines
Application History
23 events| Date | Code | Type | Description |
|---|---|---|---|
| Jan 14, 2019 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED |
| Jan 14, 2019 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| Jun 12, 2018 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Apr 18, 2018 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| Apr 18, 2018 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Apr 18, 2018 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Apr 17, 2018 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Apr 17, 2018 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Mar 28, 2018 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Mar 8, 2018 | ALIE | A | ASSIGNED TO LIE |
| Feb 28, 2018 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Feb 28, 2018 | GNRT | F | NON-FINAL ACTION E-MAILED |
| Feb 28, 2018 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Feb 28, 2018 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN |
| Feb 28, 2018 | GNEA | O | EXAMINERS AMENDMENT E-MAILED |
| Feb 28, 2018 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Feb 28, 2018 | XAEC | I | EXAMINER'S AMENDMENT ENTERED |
| Feb 28, 2018 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Feb 27, 2018 | DOCK | D | ASSIGNED TO EXAMINER |
| Feb 27, 2018 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Feb 27, 2018 | ZZZX | Z | PREVIOUS ALLOWANCE COUNT WITHDRAWN |
| Feb 16, 2018 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Feb 13, 2018 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 005
House mark used for drug delivery agents consisting of polymer compounds that facilitate the delivery of pharmaceuticals for the treatment of diseases and conditions, including ocular diseases, namely, uveitis, retinal vein occlusion, macular edema, macular disease, retinal disease, and glaucoma and diseases and conditions in joints, namely, osteoarthritis, bursitis, fibrotic diseases, and infections
First Use Anywhere:
0
First Use in Commerce:
0
Class 010
House mark for sustained drug delivery systems for pharmaceuticals
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005
010
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"PHARMACEUTICALS"